Sigma-Aldrich signs exclusive distribution agreement with Roche


Tuesday, 24 March, 2015

Following an exclusive distribution agreement, life science company Sigma-Aldrich will employ its sales, marketing and e-commerce expertise for the exclusive worldwide distribution of the Biochemical Reagents product portfolio from Roche.

The Roche portfolio includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications. Eric Green, executive vice president and president, Sigma-Aldrich Research, said the addition of the life science tools “supports our strategy to augment our portfolio with products that accelerate customer scientific research programs”.

“This agreement allows us to provide more customers with access to high-quality Roche Biochemical Reagent products through Sigma-Aldrich’s expanded e-commerce and distribution networks,” added Paul Brown, head of Roche Molecular Diagnostics. “In addition, this will provide us the flexibility to devote more resources to our primary focus areas.”

Transition of the Roche portfolio to Sigma-Aldrich is expected to take place later this year. In the interim, the products will continue to be available through existing Roche channels.

Source

Related News

Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director

Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...

Optics11 Life appoints Jacquelien ten Dam as CEO

Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd